Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). - Wikidata - awgldk - TriplyDB

Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK).

Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK).

http://www.wikidata.org/entity/Q34488558

about

Systematic review: antihypertensive drug therapy in patients of African and South Asian ethnicity Association of a CYP4A11 variant and blood pressure in black men Testing the trajectory difference in a semi-parametric longitudinal model.Loss of GSTM1, a NRF2 target, is associated with accelerated progression of hypertensive kidney disease in the African American Study of Kidney Disease (AASK).CRP polymorphisms and chronic kidney disease in the third national health and nutrition examination survey.Rate of ESRD exceeds mortality among African Americans with hypertensive nephrosclerosis.Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans.Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial.Sociodemographic factors contribute to the depressive affect among African Americans with chronic kidney disease.Limitations of analyses based on achieved blood pressure: lessons from the African American study of kidney disease and hypertension trial Variability in estimated glomerular filtration rate values is a risk factor in chronic kidney disease progression among patients with diabetes.Comparison of measured GFR, serum creatinine, cystatin C, and beta-trace protein to predict ESRD in African Americans with hypertensive CKD.Elevated depressive affect is associated with adverse cardiovascular outcomes among African Americans with chronic kidney disease.Kidney function can improve in patients with hypertensive CKD Longitudinal progression trajectory of GFR among patients with CKD.Longitudinal changes in hematocrit in hypertensive chronic kidney disease: results from the African-American Study of Kidney Disease and Hypertension (AASK).Methylenetetrahydrofolate reductase (MTHFR) polymorphism A1298C (Glu429Ala) predicts decline in renal function over time in the African-American Study of Kidney Disease and Hypertension (AASK) Trial and Veterans Affairs Hypertension Cohort (VAHC).Accuracy of a GFR estimating equation over time in people with a wide range of kidney function Medication adherence and visit-to-visit variability of systolic blood pressure in African Americans with chronic kidney disease in the AASK trial.Glomerular hyperfiltration and renal disease progression in type 2 diabetes.A Metabolome-Wide Association Study of Kidney Function and Disease in the General Population Association of BP variability with mortality among African Americans with CKD.Challenges and scientific considerations in hypertension management reflected in the 2012 recommendations of the Canadian Hypertension Education Program.Intensive blood-pressure control in hypertensive chronic kidney disease Imprecision of urinary iothalamate clearance as a gold-standard measure of GFR decreases the diagnostic accuracy of kidney function estimating equations Effect of intensive blood pressure control on cardiovascular remodeling in hypertensive patients with nephrosclerosis.Correlates of N-terminal prohormone brain natriuretic peptides in African Americans with hypertensive chronic kidney disease: the African American Study of Kidney Disease and Hypertension.Higher serum bicarbonate levels within the normal range are associated with better survival and renal outcomes in African Americans.Non-GFR Determinants of Low-Molecular-Weight Serum Protein Filtration Markers in CKD.Anti-TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy.BP Control and Long-Term Risk of ESRD and Mortality.Risk of ESRD and Mortality Associated With Change in Filtration Markers.Strict blood pressure control associates with decreased mortality risk by APOL1 genotype.Patterns of Kidney Function Decline Associated with APOL1 Genotypes: Results from AASK.Longitudinal Weight Change During CKD Progression and Its Association With Subsequent Mortality.Dynamic Prediction of Renal Failure Using Longitudinal Biomarkers in a Cohort Study of Chronic Kidney Disease.Blood pressure targets for the treatment of people with hypertension and cardiovascular disease.

P2860

Q26749491-46F90E2A-B225-4C6D-A4B7-684C3EB8162A Q28274987-317C6A35-07AA-4DA5-9A5E-43A704AADC4B Q30299953-31111B80-77AA-4896-926C-582EB21A92E4 Q30414767-805E2DF7-FE17-47B5-91E4-4C17B5FEE2D7 Q33898732-7F73602B-D1B2-480D-84C3-A2E736A5AEC6 Q34124206-2D547D3A-1687-4C6F-A4FC-38D92728B291 Q34774598-C858E750-B273-434B-ADDF-EE1724FE21D5 Q34797825-D355C5A9-D700-416E-807D-4ECB20B1B0F5 Q35043608-2C0F8408-3EF3-4BF1-8AB6-EC389D90DC0C Q35147022-F5647D8B-269E-40EA-98B3-3BCA5F0A6B15 Q35225785-506B1BE3-22A8-4A55-9F3E-1E02525362D4 Q35566332-25EF0556-7D0C-4C50-AFE1-4E40D20FD674 Q35612610-64202E72-6817-42CB-A514-893153DEE605 Q35853283-859C0745-B445-476D-BF3E-2BEE64DB0A29 Q35854689-0F2AD0A5-83D1-4DD7-B2C4-A7081775B882 Q35886023-A378F49D-3167-4E96-876C-8BFFE932FF3A Q35953241-A7FBBCC9-332C-4DD9-9221-C3E0E1E131CA Q36103479-5B4C0CE9-639A-482A-84D5-389076717EC7 Q36117545-586161D3-6AB7-41EC-82D1-DD1080572E81 Q36249519-63FB5CBE-B447-44B1-8F5F-497381EDD292 Q36746035-97597300-1E3C-4609-99F1-014E91A434AB Q36810511-FAD26D80-CC7F-47F6-846F-4A8870AAFD2B Q36845564-84FB617D-9AFF-448E-8D0E-434544799B5F Q36872087-353D848B-B3A0-4C72-BF8C-84A7ADC731B5 Q36900935-62F9729E-E981-4F31-9C59-97A179A4F89A Q37206158-9A1DCE72-5F99-4AFC-B020-A4242176135F Q37449563-ED6FD105-DA96-426A-9F2F-FAA4A4557FEA Q37590515-D9BEA073-42D6-4161-ACB2-14E79C86E04B Q38962968-764A4523-ADFA-42B6-9C08-77FB4DDE1051 Q39372162-845C3D13-D5AE-4747-8C35-9B37C99047AE Q39497189-AFB229B0-CC89-449F-84CC-C4D25077CBE4 Q40146334-D43B9371-0F23-40CF-B19B-54D63CA33879 Q40436906-CA9BDC42-8A6F-4F26-AA15-E9B444A21BC1 Q40733337-E6016B22-7657-45EA-AB24-73EFC69FB24F Q47174511-F0DB4FF4-5DC7-4ACE-9672-D657A8E916EF Q47294204-73020C73-B5AC-4EF0-BA8F-7DBCACF70AFB Q47819876-62DB55A1-E618-4328-A684-ABA0E42FB139

P2860

Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK).

http://www.wikidata.org/entity/Q34488558

description

2003 nî lūn-bûn

@nan

2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Design and statistical aspects ...... sease and Hypertension (AASK).

@ast

Design and statistical aspects ...... sease and Hypertension (AASK).

@en

Design and statistical aspects ...... idney Disease and Hypertension

@nl

type

label

Design and statistical aspects ...... sease and Hypertension (AASK).

@ast

Design and statistical aspects ...... sease and Hypertension (AASK).

@en

Design and statistical aspects ...... idney Disease and Hypertension

@nl

prefLabel

Design and statistical aspects ...... sease and Hypertension (AASK).

@ast

Design and statistical aspects ...... sease and Hypertension (AASK).

@en

Design and statistical aspects ...... idney Disease and Hypertension

@nl

P1433

Q34488558-DDE569C7-4682-4571-987D-C1D253092C11

P1476

Q34488558-856CD43B-F9FA-4A8D-8A13-557B24B645FF

P2093

Q34488558-0BCB54C5-DFF2-46EF-8D34-81764889BEA4

Q34488558-10E99D8D-A082-4E4B-8F65-AEDDBC2A91D1

Q34488558-33CF6301-B1E3-439B-943B-8167EEBCA150

Q34488558-5182CDAA-7C4D-4932-B60C-3255BFA45641

Q34488558-6D7D8436-53AD-47D6-8323-A0FCFAD6C408

Q34488558-87367A1C-1A42-403B-892F-95E34E8D352E

Q34488558-8BB552CF-5DFE-434F-BC63-37B1937B4178

Q34488558-A1C47066-1351-45EA-8AAB-F4A580CCA890

Q34488558-C5E282AF-179A-4F3E-BCAE-CB795BDE701D

Q34488558-C7DBC79A-991C-432A-82BB-E82E07C24AD7

P2860

Q34488558-0F7A5B24-6F57-4049-8926-48FB905C3CAF

Q34488558-11FA3D4D-0424-4BBF-A69C-1DF288257213

Q34488558-1D6FF3DE-E975-44D0-9DD9-75348814D099

Q34488558-22A85D64-F845-4CEC-80EB-540EF047A9B6

Q34488558-2793A828-09F4-4632-8B71-7F518FE9D63E

Q34488558-2837F799-75E8-4A04-B706-0C186B3955FD

Q34488558-2CB2D7A1-B71A-4CF0-BF35-86C5B55A89BA

Q34488558-2CE526DC-92D6-4DBF-9FF3-0EE38BA5024D

Q34488558-3168731B-5EA1-4C4B-8D67-00FF861225F2

Q34488558-4DCE1BB5-1951-4B2C-8006-17A76C8951FD

P304

Q34488558-69E90016-85C0-4ED0-8838-A65C952B17A3

P31

Q34488558-D7261026-4A57-431C-AC8F-B8D7D03361F6

P356

Q34488558-69EC8DF8-A8CD-494F-BD91-DD29304699D3

P433

Q34488558-84B2ACE0-0ABE-4078-9D57-DDBA67338D90

P478

Q34488558-E337A142-EF59-4E14-BB8D-A6591C10653B

P577

Q34488558-60F2FCD1-59B5-4BC9-8260-6CFC9EA186A7

P5875

Q34488558-60422C75-4009-453E-9A6A-984828381626

P698

Q34488558-BF058386-7B53-4254-9E64-0E5A70249758

P921

Q34488558-352313F4-8CCD-4ABC-B7DB-96F6CEAB4B47

P932

Q34488558-03456EB4-A7C0-4099-9122-C76814A318E5

P356

01.ASN.0000070080.21680.CB

P1433

Journal of the American Society of Nephrology

P1476

Design and statistical aspects ...... sease and Hypertension (AASK).

@en

P2093

George Bakris

http://www.w3.org/2001/XMLSchema#string

Gerald J Beck

http://www.w3.org/2001/XMLSchema#string

Jackson T Wright

http://www.w3.org/2001/XMLSchema#string

Janice Douglas

http://www.w3.org/2001/XMLSchema#string

Jennifer J Gassman

http://www.w3.org/2001/XMLSchema#string

Julia Lewis

http://www.w3.org/2001/XMLSchema#string

Ken Jamerson

http://www.w3.org/2001/XMLSchema#string

Lawrence Agodoa

http://www.w3.org/2001/XMLSchema#string

Michael Kutner

http://www.w3.org/2001/XMLSchema#string

Otelio S Randall

http://www.w3.org/2001/XMLSchema#string

P2860

A multiple testing procedure for clinical trials

Random-effects models for longitudinal data

Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat

Antihypertensive treatment: does the J-curve exist?

Systemic hypertension and the kidney in black patients.

Renal protection in essential hypertension: how do angiotensin-converting enzyme inhibitors compare with calcium antagonists?

An approximate generalized linear model with random effects for informative missing data.

Target organ damage in black hypertensives.

Beta-blockers and the kidney.

Essential hypertension: a renal disease? A review and update of the evidence.

P304

S154-65

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/01.ASN.0000070080.21680.CB

http://www.w3.org/2001/XMLSchema#string

P433

7 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2003-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10697743

http://www.w3.org/2001/XMLSchema#string

P698

12819322

http://www.w3.org/2001/XMLSchema#string

P921

P932

1417393

http://www.w3.org/2001/XMLSchema#string